Study summary

A blood test after surgery sorted high-risk from low-risk stage III colon cancer

DYNAMIC-III trial (ctDNA blood test) · 968 people, phase 2/3 · Published October 2025, Nature Medicine

87%free of recurrence at 3 years if ctDNA-negative, vs 49% if positive

What was tested

Circulating tumor DNA (ctDNA) blood testing after surgery to lighten chemotherapy for ctDNA-negative people and intensify it for ctDNA-positive people, against standard care.

What they found

What it means

ctDNA predicts risk well; how to act on it is still being tested.

Nat Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.